Theradiag acquires Prestizia - MarketLine Financial Deals

Theradiag acquires Prestizia

Theradiag acquires Prestizia - MarketLine Financial Deals
Theradiag acquires Prestizia
Published Jun 27, 2012
2 pages — Published Jun 27, 2012
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Theradiag, a theranostics and in vitro diagnostics company, has acquired Prestizia, a biotechnology company developing microRNA1 technology, from investment fund Holding Incubatrice Biotechnologie et Pharmacie. All entities are based in France.

  
Source:
Document ID
MA114747_120703
Country
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Theradiag acquires Prestizia" Jun 27, 2012. Alacra Store. Dec 08, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Theradiag-acquires-Prestizia-2052-83549>
  
APA:
MarketLine Financial Deals. (2012). Theradiag acquires Prestizia Jun 27, 2012. New York, NY: Alacra Store. Retrieved Dec 08, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Theradiag-acquires-Prestizia-2052-83549>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.